Ackermans & van Haaren and NRW.Bank led a €36m seed financing round in DISCO Pharmaceuticals.

Ackermans & van Haaren, a diversified investment group, and NRW.Bank, a venture capital firm, led a €36m seed financing round in DISCO Pharmaceuticals, a company focused on developing targeted cancer therapies using cell surfaceome discovery technology, with participation from Sofinnova Partners, AbbVie Ventures, M Ventures, and Panakes Partners. “DISCO’s platform can open entirely new therapeutic areas by revealing previously unknown targets on the cancer cell surface and their biology. With the addition of Mark Manfredi as CEO, DISCO is poised to become a leader in surfaceome-guided oncology drug development, and we look forward to supporting the company on its path towards the clinic,” Lenny Van Steenhuyse, Ackermans & van Haaren Investment Manager.